From Dreams to Psychedelics: Tommaso’s Academic Odyssey
Tommaso Barba, a visionary in psychedelic research, advances knowledge and accessibility, bridging diverse fields for a brighter future.
Interviews
Changing Psychedelic Policy for 450 Million People
PsychedelicsEUROPE is shaping the European psychedelic landscape, influencing policies, and addressing mental health crises. Their MEP action group aims to accelerate EU regulatory changes.
Meet the psychedelic investor open about his experiences
Bek Muslimov is a Co-Founding Partner at Leafy Tunnel. Over the past 7 years, he’s been investing in European life sciences and technology companies. Floris Wolswijk, spoke with Bek to learn about Leafy Tunnel’s investment strategy and what brought him to invest in psychedelics.
Meet the man making natural psychedelics in bioreactors
Itay Hecht is the CEO & Co-Founder of PsyRx, an Israeli pharmaceutical producer of natural psychedelics – ibogaine and psilocybin specifically. As there will be a need for natural – but GMP grade – psychedelics, PsyRx is filling that gap.
How to make psychedelics at scale. Insights from Peter van der Heyden – CSO at Psygen.
Peter is the CSO and co-founder of Psygen – where they make psychedelic APIs – active pharmaceutical ingredients – for research and at scale. Dive into our interview to learn about the challenges of scaling up the production of psychedelics.
Meet the neuroscientist & army officer helping veterans get the treatment they need at Heroic Hearts
We had the chance to speak with Dr Grace Blest-Hopley at Plant Medicine Week to discuss the work she and her colleagues are doing at Heroic Hearts, how psychedelics are helping veterans with traumatic brain injury, and more.
Meet the psychiatrist investigating MDMA-assisted therapy for depression
Tor-Morten shares vital information about the upcoming MDMA-AT trial for major depression. May this psychedelic also work for depression?
Learn what psychoneuroimmunology is from Attila Szabo
Attila Szabo shares the most interesting insights on psychoneuroimmunology & what led him to become a psychedelic researcher
Psychedelics and VR – Interview with David Glowacki
To better understand the science of psychedelics, and how we can make the bridge to implementing them in practice, Blossom is conducting a series of interviews with psychedelic scientists. Our editor-at-large, George Fejer, speaks to David Glowacki, one of the world’s leaders in the use of virtual reality applied to scientific simulation and visualization.
The secrets of kratom – Interview with Jay McLaughlin
To better understand the science of psychedelics, and how we can make the bridge to implementing them in practice, Blossom is conducting a series of interviews with psychedelic scientists. Our editor-at-large, George Fejer, speaks to Dr. Jay McLaughlin, Professor of Pharmacodynamics at the University of Florida, and one of the leading experts on kratom.